Orthosteric–allosteric dual inhibitors of PI5P4Kγ with potent antitumor activity in non-small cell lung cancer
Journal of Advanced Research · 2026-06 · 84 · 1105-1126
DOI: 10.1016/j.jare.2025.09.024 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Advanced Research, 2026-06. Verfasst von Liang Xiong und 8 weiteren Autor:innen. Beteiligte Einrichtung: State Key Laboratory of Discovery and Utilization of Functional Components in Traditional Chinese Medicine, School of Pharmaceutical Sciences, Guizho…. Hauptthemen laut MEDLINE: Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Antineoplastic Agents, Protein Kinase Inhibitors. Die Arbeit nennt 42 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: National Natural Science Foundation of China, Natural Science Research Project of Guizhou Province, Natural Science Foundation of Guizhou Province.
Abstract (Originalsprache)
INTRODUCTION: Phosphatidylinositol 5-phosphate 4-kinase type II gamma (PI5P4Kγ) has emerged as a promising therapeutic target in oncology due to its key role in cancer progression. However, currently available inhibitors targeting either the orthosteric or allosteric sites of PI5P4Kγ suffer from limited in vitro activity and in vivo validation. OBJECTIVES: This study aimed to develop a highly potent and selective PI5P4Kγ inhibitor capable of simultaneously engaging both the orthosteric and allosteric sites, as well as to validate their potential in therapy for non-small cell lung cancer (NSCLC) were investigated. METHODS: Through the structural modification of the propionamide side chain of the pyridine ring and the N3 substituent of the quinazolinone, the structure-activity relationship (SAR) was elucidated, leading to the identification of the target compound n40. The binding mode of n40 to PI5P4Kγ, was elucidated by X-ray crystallography. In vitro effects were assessed through KINOMEscan Technology, cell proliferation, apoptosis, and EMT analysis. In vivo efficacy was evaluated using an HCC827 xenograft mouse model. Both single-dose (up to 400 mg/kg) and repeated-dose (20-180 mg/kg/day for 28 days) toxicity studies of n40 were conducted in mice, with comprehensive monitoring of physiological parameters and organ toxicity indices. RESULTS: Compound n40 exhibited a strong binding affinity for PI5P4Kγ (Kd = 6.55 nM), with 3,000-fold selectivity over other two isoforms. Additionally, it displayed sub-50 nM antiproliferative activity in NSCLC cells with higher PI5P4Kγ levels. X-ray crystallography revealed n40 simultaneously binds to both orthosteric and a novelallosteric pocket. Functionally, n40 induced S-phase arrest, apoptosis, and EMT reversal and PI3K/AKT/mTOR signaling inhibition in a PI5P4Kγ-dependent manner. In HCC827 xenografts, n40 achieved > 60 % tumor growth inhibition without any observed toxicity. CONCLUSION: This study establishes PI5P4Kγ as a druggable target in NSCLC and demonstrates that dual orthosteric-allosteric targeting is a viable strategy to achieve potent and selective PI5P4Kγ inhibitors.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- State Key Laboratory of Discovery and Utilization of Functional Components in Traditional Chinese Medicine, School of Pharmaceutical Sciences, Guizhou Medical University, Natural Products Research Center of Guizhou Prov…
- State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai 201203, China.
- State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai 201203, China. Electronic address: ycxu@simm.ac.cn.
Förderung
- National Natural Science Foundation of China
- Natural Science Research Project of Guizhou Province
- Natural Science Foundation of Guizhou Province
Zitieren
APA
Xiong, L., Tang, L., Zhao, W., Wang, R., Cheng, C., Wang, D., Xu, Y., Tang, L., & Fan, Y. (2026). Orthosteric–allosteric dual inhibitors of PI5P4Kγ with potent antitumor activity in non-small cell lung cancer. Journal of Advanced Research, 84, 1105-1126. https://doi.org/10.1016/j.jare.2025.09.024
Vancouver
Xiong L, Tang L, Zhao W, Wang R, Cheng C, Wang D, et al. Orthosteric–allosteric dual inhibitors of PI5P4Kγ with potent antitumor activity in non-small cell lung cancer. Journal of Advanced Research. 2026;84:1105-1126. doi:10.1016/j.jare.2025.09.024
BibTeX
@article{Xiong2026,
author = {Xiong, Liang and Tang, Lei and Zhao, Wenfeng and Wang, Rongtao and Cheng, Cheng and Wang, Daoping and Xu, Yechun and Tang, Lei and Fan, Yanhua},
title = {Orthosteric–allosteric dual inhibitors of PI5P4Kγ with potent antitumor activity in non-small cell lung cancer},
journal = {Journal of Advanced Research},
year = {2026},
volume = {84},
pages = {1105--1126},
doi = {10.1016/j.jare.2025.09.024}
}
EUVIMED